Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab

Ophthalmology

Volumn 122, Issue 3, 2015, Pages 589-594.e1

  Gillies, Mark C ^a   Campain, Anna ^a   Walton, Richard ^a   Simpson, Judy M ^b   Arnold, Jennifer J ^c   Guymer, Robyn H ^d   McAllister, Ian L ^e   Hunyor, Alex P ^a,f   Essex, Rohan W ^g   Morlet, Nigel ^h   Barthelmes, Daniel ^a,i  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Marsden Eye Specialists   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Retina Associates   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; BLINDNESS; CLINICAL PRACTICE; CONFERENCE PAPER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETREATMENT; TIME; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RETREATMENT; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84924035773     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.10.001     Document Type: Conference Paper

References (18)

1. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
2. J.S. Heier, W.L. Clark, and D.S. Boyer Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS Study Ophthalmology 121 2014 1414 1420
3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
4. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
6. D.M. Brown, and C.D. Regillo Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients Am J Ophthalmol 144 2007 627 637
7. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
8. O.P. Gupta, G. Shienbaum, and A.H. Patel A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact Ophthalmology 117 2010 2134 2140
9. P. Mitchell, J.F. Korobelnik, and P. Lanzetta Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials Br J Ophthalmol 94 2010 2 13
10. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
11. M.C. Gillies, R. Walton, and J. Liong Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project. Retina 34 2014 188 195
12. M.C. Gillies, R. Walton, J.M. Simpson Fight Retinal Blindness! Project Investigators Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes Invest Ophthalmol Vis Sci 54 2013 5754 5760
13. M.C. Gillies, R.J. Walton, and J.J. Arnold Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort Ophthalmology 121 2014 676 681
14. W.S. Cleveland, E. Grosse, and W.M. Shyu Local regression models J.M. Chambers, T. Hastie, Statistical Models in S 1992 Wadsworth & Brooks/Cole Pacific Grove, CA 309 376
15. S. Hollis, and F. Campbell What is meant by intention to treat analysis? Survey of published randomised controlled trials BMJ 319 1999 670 674
16. I. Krebs, C. Glittenberg, and S. Ansari-Shahrezaei Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration Br J Ophthalmol 97 2013 1443 1446
17. J.D. Gass Pathogenesis of disciform detachment of the neuroepithelium Am J Ophthalmol 63 Suppl 1967 1 139
18. Macular Photocoagulation Study Group Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group Arch Ophthalmol 109 1991 1242 1257